736 related articles for article (PubMed ID: 15969889)
21. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
[TBL] [Abstract][Full Text] [Related]
22. Treatment implications for radiation-induced nausea and vomiting in specific patient groups.
Horiot JC; Aapro M
Eur J Cancer; 2004 May; 40(7):979-87. PubMed ID: 15093572
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.
Slatkin NE
J Support Oncol; 2007 May; 5(5 Suppl 3):1-9. PubMed ID: 17566383
[TBL] [Abstract][Full Text] [Related]
24. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy-induced emesis. An overview.
Feyer P; Zimmermann JS; Titlbach OJ; Buchali A; Hinkelbein M; Budach V
Strahlenther Onkol; 1998 Nov; 174 Suppl 3():56-61. PubMed ID: 9830459
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
Jordan K; Kasper C; Schmoll HJ
Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
[TBL] [Abstract][Full Text] [Related]
27. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
28. [Modern aspects of antiemetic therapy].
Aleksandrović J; Dagović A; Jeremić B
Srp Arh Celok Lek; 1998; 126(7-8):295-303. PubMed ID: 9863398
[TBL] [Abstract][Full Text] [Related]
29. Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Sankhala KK; Pandya DM; Sarantopoulos J; Soefje SA; Giles FJ; Chawla SP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1607-14. PubMed ID: 19929449
[TBL] [Abstract][Full Text] [Related]
30. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
31. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
32. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
Saito M; Tsukuda M
Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
[TBL] [Abstract][Full Text] [Related]
33. [Management of emesis in cancer patients].
Slimane K; Perez A; Ruffié P; di Palma M
Bull Cancer; 2004 May; 91(5):403-8. PubMed ID: 15281279
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.
Schwartzberg LS
J Support Oncol; 2007 Feb; 5(2 Suppl 1):5-12. PubMed ID: 17366928
[TBL] [Abstract][Full Text] [Related]
35. 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment.
Aapro M
Oncology; 2005; 69(2):97-109. PubMed ID: 16131816
[TBL] [Abstract][Full Text] [Related]
36. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract][Full Text] [Related]
37. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
[TBL] [Abstract][Full Text] [Related]
38. International patterns of practice in the management of radiation therapy-induced nausea and vomiting.
Dennis K; Zhang L; Lutz S; van Baardwijk A; van der Linden Y; Holt T; Arnalot PF; Lagrange JL; Maranzano E; Liu R; Wong KH; Wong LC; Vassiliou V; Corn BW; De Angelis C; Holden L; Wong CS; Chow E
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e49-60. PubMed ID: 22704982
[TBL] [Abstract][Full Text] [Related]
39. Nausea: the neglected symptom?
Foubert J; Vaessen G
Eur J Oncol Nurs; 2005 Mar; 9(1):21-32. PubMed ID: 15774338
[TBL] [Abstract][Full Text] [Related]
40. Management of radiation-induced nausea and vomiting.
Abdelsayed GG
Exp Hematol; 2007 Apr; 35(4 Suppl 1):34-6. PubMed ID: 17379085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
